CSS
RVPH

Cubist Systematic Strategies’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Cubist Systematic Strategies’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,930
Closed -$164K – 4351
2022
Q4 		$164K Buy
+1,930
New +$147K ﹤0.01% 3671

Other funds holding RVPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ECM
EMC Capital Management Houston, Texas $253M AUM
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Cubist Systematic Strategies's RVPH Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q1 2023, closing a stake of 1,930 shares — an estimated $164K sold.

Cubist Systematic Strategies first reported a position in RVPH in Q4 2022 and held it in 1 quarter. The position peaked at $164K in Q4 2022. 21 funds tracked by Wall St. Rank hold RVPH as of Q1 2023.

  • Cubist Systematic Strategies reported no remaining REVIVA PHARMA HLDGS INC position as of Q1 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,930 REVIVA PHARMA HLDGS INC shares in Q1 2023, an estimated $164K.
  • Cubist Systematic Strategies first reported a position in REVIVA PHARMA HLDGS INC in Q4 2022 and held it in 1 quarter.
  • Cubist Systematic Strategies's REVIVA PHARMA HLDGS INC position peaked at $164K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.